- Overview
-
Women who use substances in pregnancy are an under-studied group that face unique contexts and barriers to services and supports. Left untreated, severe substance use disorders in pregnancy can present significant harms both to mother and baby, including overdose and/or mortality. It is imperative that all women have access to treatments and services that are effective, safe, and acceptable. The goal of our research is to generate evidence to support treatments for pregnant women who use substances, that will allow women with substance use disorders to bond with, and parent their newborns.
- Publications
-
Rapid transition from high-dose methadone to buprenorphine-naloxone and long-acting buprenorphine in a perinatal patient with opioid use disorder: A case report
Heroin Addiction and Related Clinical Problems
Kreim, S. and Gordon, S. and Carter, N. and Dreyer, M. and Ketch, J. and Patricelli, C.J.
DOI: 10.62401/2531-4122-2024-67
2024Perinatal injectable opioid agonist therapy (iOAT) treatment experience: A qualitative study
Heroin Addiction and Related Clinical Problems
Patricelli, C. and Liu, R. and Gordon, S. and Carter, N. and Stewart, K. and Gouin, I. and Paquette, V. and Bone, J. and Urbanoski, K.
DOI: 10.62401/2531-4122-2024-46
2024Neonatal Opioid Withdrawal Syndrome (NOWS) Monitoring Not Requiring NICU Admissions: Examining Rooming-in as Standard Care
Canadian Journal of Addiction
Patricelli, C.J. and Ricci, T.A. and Doerksen, J. and Ziabakhsh, S. and Everett, R. and Cattoni, E. and Hamilton, D. and Carter, N. and Wittmann, L. and Berkman, J. and Gordon, S. and Abrahams, R.
DOI: 10.1097/CXA.0000000000000199
2024Perinatal Injectable Opioid Agonist Therapy (iOAT) Administration: A Case Series
Journal of Addiction Medicine
Patricelli, C.J. and Chai, J. and Gordon, S. and Gouin, I.J. and Carter, N. and Stewart, K. and Paquette, V. and Urbanoski, K. and Albert, A.
DOI: 10.1097/ADM.0000000000001152
2023Breastfeeding on Injectable Opioid Agonist Therapy: A Case Report
Journal of Addiction Medicine
Patricelli, C.J. and Gouin, I.J. and Gordon, S. and Carter, N. and Albert, A. and Paquette, V. and Stewart, K. and George, S. and Urbanoski, K.
DOI: 10.1097/ADM.0000000000001055
2023 - Research
-
Injectable Opioid Agonist Therapy in a Perinatal Population
Injectable opioid agonist therapy (iOAT) is an evidence-based treatment option for severe opioid use disorder (OUD). It is the highest intensity treatment option currently available in Canada for those with severe OUD, and has been successfully introduced in specialized clinics as a way to stabilize those for whom oral opioid agonist treatments have not been effective. However, there is a gap in the literature concerning iOAT administration efficacy and outcomes in perinatal populations. The iOAT-APP study aims to gather critical practice-based evidence for the administration of iOAT in pregnancy.Research Group MembersGurleen Dhami, INSPIRE TRAINEE
Asha Rai, INSPIRE Trainee
Gabi Tremblay
Alexsa Zurowski, START Program Trainee
Congratulations CIHR Fall 2023 Project Grant recipients
Congratulations to the BC Children’s Hospital Research Institute (BCCHR) and Women’s Health Research Institute (WHRI) investigators and their teams who were awarded $11 million in funding through the Canadian Institutes of Health Research (CIHR) Fall 2023 Project Grant competition.
